Radius Health (RDUS) Receives Consensus Recommendation of “Hold” from Analysts

Radius Health (NASDAQ:RDUS) has been assigned an average recommendation of “Hold” from the twelve brokerages that are currently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $54.25.

A number of research firms have recently commented on RDUS. ValuEngine downgraded shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Tuesday. Cantor Fitzgerald reiterated a “buy” rating and issued a $58.00 target price on shares of Radius Health in a research note on Friday, May 11th. Zacks Investment Research downgraded shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Wednesday, May 2nd. Morgan Stanley cut their target price on shares of Radius Health from $61.00 to $59.00 and set an “overweight” rating for the company in a research note on Friday, March 23rd. Finally, BidaskClub downgraded shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Wednesday, May 2nd.

Radius Health stock opened at $28.91 on Thursday. Radius Health has a one year low of $24.66 and a one year high of $49.16. The company has a debt-to-equity ratio of 0.87, a current ratio of 6.55 and a quick ratio of 6.41. The stock has a market cap of $1.32 billion, a PE ratio of -4.98 and a beta of 1.27.

Radius Health (NASDAQ:RDUS) last posted its quarterly earnings data on Thursday, May 10th. The biopharmaceutical company reported ($1.37) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.46) by $0.09. Radius Health had a negative net margin of 706.11% and a negative return on equity of 108.95%. The company had revenue of $14.50 million during the quarter, compared to the consensus estimate of $13.80 million. During the same period in the prior year, the business posted ($1.32) EPS. sell-side analysts expect that Radius Health will post -5.24 earnings per share for the current fiscal year.

In other news, major shareholder Growth N. V. Biotech bought 80,000 shares of the business’s stock in a transaction that occurred on Friday, March 2nd. The stock was acquired at an average cost of $32.52 per share, for a total transaction of $2,601,600.00. Following the purchase, the insider now owns 5,853,799 shares of the company’s stock, valued at approximately $190,365,543.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Growth N. V. Biotech bought 50,000 shares of the business’s stock in a transaction that occurred on Thursday, April 5th. The stock was purchased at an average price of $36.58 per share, with a total value of $1,829,000.00. Following the completion of the purchase, the insider now directly owns 5,903,799 shares in the company, valued at approximately $215,960,967.42. The disclosure for this purchase can be found here. Insiders purchased a total of 230,000 shares of company stock valued at $7,538,800 over the last quarter. 3.42% of the stock is currently owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. raised its holdings in Radius Health by 0.9% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 182,575 shares of the biopharmaceutical company’s stock valued at $5,801,000 after acquiring an additional 1,674 shares during the period. California Public Employees Retirement System raised its holdings in Radius Health by 2.3% in the 4th quarter. California Public Employees Retirement System now owns 74,400 shares of the biopharmaceutical company’s stock valued at $2,364,000 after acquiring an additional 1,700 shares during the period. Jane Street Group LLC raised its holdings in Radius Health by 24.7% in the 4th quarter. Jane Street Group LLC now owns 10,043 shares of the biopharmaceutical company’s stock valued at $319,000 after acquiring an additional 1,988 shares during the period. Swiss National Bank raised its holdings in Radius Health by 5.6% in the 1st quarter. Swiss National Bank now owns 57,000 shares of the biopharmaceutical company’s stock valued at $2,049,000 after acquiring an additional 3,000 shares during the period. Finally, Raymond James & Associates raised its holdings in Radius Health by 44.5% in the 4th quarter. Raymond James & Associates now owns 15,224 shares of the biopharmaceutical company’s stock valued at $484,000 after acquiring an additional 4,692 shares during the period.

About Radius Health

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply